Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Cash (2016 - 2025)

Historic Change in Cash for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $26.6 million.

  • Heron Therapeutics' Change in Cash rose 26100.61% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year increase of 29003.07%. This contributed to the annual value of -$2.9 million for FY2024, which is 12159.54% down from last year.
  • Latest data reveals that Heron Therapeutics reported Change in Cash of $26.6 million as of Q3 2025, which was up 26100.61% from -$2.8 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Change in Cash registered a high of $131.4 million during Q2 2021, and its lowest value of -$69.0 million during Q4 2021.
  • Its 5-year average for Change in Cash is -$3.3 million, with a median of -$6.2 million in 2023.
  • In the last 5 years, Heron Therapeutics' Change in Cash tumbled by 79049.71% in 2021 and then surged by 106987.42% in 2023.
  • Heron Therapeutics' Change in Cash (Quarter) stood at -$69.0 million in 2021, then soared by 49.19% to -$35.1 million in 2022, then skyrocketed by 82.37% to -$6.2 million in 2023, then soared by 100.99% to $61000.0 in 2024, then skyrocketed by 43427.87% to $26.6 million in 2025.
  • Its Change in Cash was $26.6 million in Q3 2025, compared to -$2.8 million in Q2 2025 and -$6.5 million in Q1 2025.